Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Ascendis Pharma AS (ASND)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Ascendis Pharma AS's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
135.74 +0.12    +0.09%
14:25:41 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
ISIN:  US04351P1012 
CUSIP:  04351P101
  • Volume: 130,963
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 131.91 - 139.91
Ascendis Pharma AS 135.74 +0.12 +0.09%
Wedbush Stick to Their Buy Rating for Ascendis Pharma
Wedbush Stick to Their Buy Rating for Ascendis Pharma By Investing.com - Nov 19, 2021

Wedbush analyst Liana Moussatos reiterated a Buy rating on Ascendis Pharma (NASDAQ:ASND) on Friday, setting a price target of $191, which is approximately 28.50% above the present share price of...

Ascendis Pharma AS Earnings Beat, Revenue Misses In Q3
Ascendis Pharma AS Earnings Beat, Revenue Misses In Q3 By Investing.com - Nov 10, 2021

Investing.com - Ascendis Pharma (NASDAQ:ASND) AS reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Ascendis Pharma AS...

Wedbush Stick to Their Buy Rating for Ascendis Pharma
Wedbush Stick to Their Buy Rating for Ascendis Pharma By Investing.com - Oct 18, 2021

Wedbush analyst Liana Moussatos maintained a Buy rating on Ascendis Pharma (NASDAQ:ASND) on Monday, setting a price target of $191, which is approximately 19.38% above the present share price of...

Evercore ISI Stick to Their Buy Rating for Ascendis Pharma
Evercore ISI Stick to Their Buy Rating for Ascendis Pharma By Investing.com - Aug 26, 2021

Evercore ISI analyst Joshua Schimmer reiterated a Buy rating on Ascendis Pharma (NASDAQ:ASND) on Thursday, setting a price target of $210, which is approximately 69.81% above the present share price...

Wedbush Stick to Their Buy Rating for Ascendis Pharma
Wedbush Stick to Their Buy Rating for Ascendis Pharma By Investing.com - Aug 26, 2021

Wedbush analyst Liana Moussatos reiterated a Buy rating on Ascendis Pharma (NASDAQ:ASND) on Thursday, setting a price target of $187, which is approximately 51.21% above the present share price of...

Ascendis Pharma AS Earnings Miss, Revenue Beats In Q2
Ascendis Pharma AS Earnings Miss, Revenue Beats In Q2 By Investing.com - Aug 25, 2021

Investing.com - Ascendis Pharma (NASDAQ:ASND) AS reported on Wednesday second quarter earnings that missed analysts' forecasts and revenue that topped expectations. Ascendis Pharma AS announced...

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ASND Comments

Write your thoughts about Ascendis Pharma AS
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
태휘 권
태휘 권 Oct 09, 2019 11:31PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
why does ascendis announce of pediatric growth hormone data ?
MJ Levine
MJ Levine Oct 09, 2019 11:31PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I'll ***** why? 🤣
태휘 권
태휘 권 Oct 09, 2019 11:29PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
does anyone know pediatric growth hormone 2-year data ?
Trader Canarias
Trader Canarias Mar 05, 2019 8:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
u can see my trades in facebook and twitter
Trader Canarias
Trader Canarias Mar 05, 2019 8:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
looking for shorts selling
Romulo Lisboa
Romulo Lisboa Mar 04, 2019 10:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buying or selling?
Sarah Singbell
Sarah Singbell Mar 04, 2019 10:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
well look at what we have here!! ill be watching you more closely.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email